Cereton (Choline alfoscerate)

Instructions for Cereton (Choline alfoscerate)

English product name
Cereton

Release Form
four hundred mg: 14, 28, 42 or fifty

Description Cereton

The capsules are soft, oval, yellow or yellow with a light brown colour; the contents of the capsules are an oily transparent, colourless or slightly coloured liquid.

1 cap.
choline alfoscerate 400 mg
Auxiliary substances: glycerol - 50 mg, water purified - until the content mass is 590 mg.

The capsule contains gelatin, sorbitol, glycerol, methylparahydroxybenzoate, propyl parahydroxybenzoate, titanium dioxide, iron oxide yellow dye, purified water.

ATC codes
N07AX02 Choline alfoscerate

Clinical-pharmacological groups / Group affiliation
Nootropic drug. Central Action Cholinomimetic

Active substance
choline alfoscerate

Pharmaco-therapeutic group Cereton

Nootropic agent

Storage Conditions
The drug should be stored in a place inaccessible to children, protected from light at a temperature not higher than 25 ° C.

Pharmacological effect Cereton

Nootropic drug. Central cholinovulator containing 40.5% metabolically protected choline.

Metabolic protection promotes the release of choline in the brain. Provides acetylcholine and phosphatidylcholine synthesis in neuronal membranes, improves blood flow and enhances metabolic processes in the CNS, activates the reticular formation. It increases the linear rate of blood flow on the side of traumatic brain injury, promotes the normalization of the spatiotemporal characteristics of spontaneous bioelectrical activity of the brain, the regression of focal neurological symptoms and the restoration of consciousness. It has a positive effect on cognitive and behavioural responses of patients with vascular diseases of the brain (discirculatory encephalopathy and residual phenomena of cerebral circulation disorders).

Testimony Cereton

• Recovery periods of severe traumatic brain injury and ischemic stroke, 
• recovery period of haemorrhagic stroke, 
• occurring with focal semi-concussive symptoms or symptoms of brain stem lesions;
• psychoorganic syndrome amid degenerative and involutive brain changes;
• cognitive disorders (impairments in thought function, memory, confusion, disorientation, decreased motivation, initiative, and
• ability to focus), including dementia and encephalopathy; an old pseudo-melancholy.

Method of use, course and dosage Cereton

During the recovery period, Cereton® is prescribed eight hundred mg in the morning and four hundred mg in the afternoon for six months.
For chronic cerebrovascular insufficiency and dementia syndrome, Cereton® is given four hundred mg three times a day, preferably after meals, for three to

• Nosology (ICD codes)
• F01
• Vascular dementia
• F03
• Dementia, unspecified
• F07
• Personality and behavioral disorders due to disease, damage or dysfunction of the brain
• G92
• Toxic encephalopathy
• G93.4
• Encephalopathy, unspecified
• I63
• brain infarction
• I67.4
• Hypertensive encephalopathy
• I69
• Consequences of cerebrovascular diseases
• S06
• Intracranial injury
• T90
• Sequelae of head trauma